Published in J Lipid Res on March 25, 2014
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med (2017) 0.76
Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators. J Med Chem (2016) 0.75
Gaucher-Associated Parkinsonism. Cell Mol Neurobiol (2015) 0.75
Did α-Synuclein and Glucocerebrosidase Coevolve? Implications for Parkinson's Disease. PLoS One (2015) 0.75
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 6.45
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (2000) 4.27
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol (2007) 3.94
Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One (2009) 2.90
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab (2004) 2.46
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood (2010) 2.38
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci (2004) 2.29
Parkinsonism among Gaucher disease carriers. J Med Genet (2004) 2.24
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol (2012) 2.20
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A (2006) 1.96
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A (2011) 1.90
High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol (2007) 1.85
α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci (2011) 1.79
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (1997) 1.70
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol (2010) 1.63
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol Dis (2012) 1.58
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1999) 1.53
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem (2007) 1.53
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A (2013) 1.45
Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye. PLoS One (2013) 1.45
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis (2004) 1.45
Lipid and cholesterol trafficking in NPC. Biochim Biophys Acta (2004) 1.44
Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol (2008) 1.42
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J (2010) 1.42
GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry (2007) 1.40
Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem (2009) 1.39
Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry (2009) 1.38
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. J Org Chem (2007) 1.28
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord (2011) 1.22
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab (2010) 1.20
Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis (2012) 1.15
ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. Drugs Future (2010) 1.15
Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis (2010) 1.14
Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem (2012) 1.14
Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis (2010) 1.13
Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem (2011) 1.13
Gaucher disease and parkinsonism. Mol Genet Metab (2005) 1.13
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. J Neuropathol Exp Neurol (2012) 1.12
Isofagomine induced stabilization of glucocerebrosidase. Chembiochem (2008) 1.09
Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab (2012) 1.08
Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis (2005) 1.07
Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J Lipid Res (2013) 1.07
High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One (2012) 1.07
The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica (2007) 1.06
Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS One (2011) 1.06
A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci (2012) 1.05
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med (2009) 1.05
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis (2012) 1.02
Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci (2003) 1.00
β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem (2013) 0.97
Molecular basis for the glycosphingolipid-binding specificity of α-synuclein: key role of tyrosine 39 in membrane insertion. J Mol Biol (2011) 0.96
Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis (2010) 0.93
Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. Am J Pathol (2009) 0.92
Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS One (2011) 0.92
Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis (2009) 0.91
Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis (2007) 0.91
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One (2012) 0.89
Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol Genet Metab (2012) 0.89
Clearance of mutant proteins as a therapeutic target in neurodegenerative diseases. Arch Neurol (2010) 0.89
Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol Genet Metab (2010) 0.89
Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res (2012) 0.87
Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase. Biochem Pharmacol (2006) 0.87
Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res (2011) 0.87
Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease. ChemMedChem (2009) 0.86
Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm (2011) 0.83
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Glycosphingolipid disorders of the brain. Subcell Biochem (2008) 0.81
Clinical diversity in Gaucher's disease. Johns Hopkins Med J (1980) 0.80
Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem Res (2013) 0.80
Parkinsonism syndrome in heterozygotes for Niemann-Pick C1. J Neurol Sci (2013) 0.79
Gangliosides' protection against lysosomal pathology of synucleinopathies. Autophagy (2009) 0.76